Details
August 13-19, 2020
National Broadcast to Announce the Approval of a Second Indication for TAZVERIK™ (tazemetostat)
Hosted by Epizyme
WEBINAR - Multiple Broadcast Times
Learn more about a new treatment option for your relapsed or refractory follicular lymphoma (FL) patients
In this Live Broadcast, Dr. Pagel, Dr. Burke, and Dr. Kurtin will:
- Review the Prescribing Information for this new treatment available for relapsed or refractory FL patients
- Present clinical safety and efficacy data in this patient population
- Provide important dosing and patient counseling information
- Discuss a hypothetical patient case study
2020-08-13 17:00:00 2020-08-19 21:00:00 America/Detroit National Broadcast to Announce the Approval of a Second Indication for TAZVERIK™ (tazemetostat) Learn more about a new treatment option for your relapsed or refractory follicular lymphoma (FL) patients In this Live Broadcast, Dr. Pagel, Dr. Burke, and Dr. Kurtin will: Review the Prescribing Information for this new treatment available for relapsed or refractory FL patients Present clinical safety and efficacy data in this patient population Provide important dosing and patient counseling information Discuss a hypothetical patient case study Click here to register View the flier WEBINAR - Multiple Broadcast Times
